Medicine
Eovist 1814.3 mg/10 mL injection
Eovist 1814.3 mg/10 mL injection is a prescription medicine containing Gadoxetate for intravenous use, marketed by Bayer HealthCare Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25° C (68°F to 77° F), excursions permitted to 15°C to 30° C…
Key facts
- Active ingredient (INN)
- Gadoxetate
- Brand
- Eovist
- Strength
- 1814.3 mg/10 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 5 vials of 10 mL
- Marketing authorisation holder
- Bayer HealthCare Pharmaceuticals
- Manufacturer
- Bayer HealthCare Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25° C (68°F to 77° F), excursions permitted to 15°C to 30° C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V08CA10 Gadoxetate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 July 2008
- Identifiers
- DailyMed set ID 6218b1e1-cbc3-4c14-bec7-528ac163a561NDC 50419-320Application NDA022090
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 vial, single-dose in 1 box / 10 mL in 1 vial, single-dose | 50419-320-05 | Bayer HealthCare Pharmaceuticals | 3 July 2008 |
| 5 vial, single-dose in 1 box / 10 mL in 1 vial, single-dose | 50419-320-75 | Bayer HealthCare Pharmaceuticals | 3 July 2008 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 3 July 2008 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Gadoxetate
Clinical summary
Gadoxetate is a gadolinium-based contrast agent indicated in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease. MedsAcross supplies Gadoxetate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GadoxetateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EOVIST prescribing information (Bayer HealthCare Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Eovist 1814.3 mg/10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.